espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.

In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases.

Journavx is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use